Benzinga | Aug 5, 2021 08:14AM EDT

Credit Suisse Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $75

Credit Suisse analyst Judah Frommer maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and raises the price target from $72 to $75.